summit clinical trial tirzepatide In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide Outperforms Dulaglutide on Cardiorenal
Pay in 4 interest-free payments of $5.82 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
![summit clinical trial tirzepatide In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide Outperforms Dulaglutide on Cardiorenal](https://cdn.sanity.io/images/0vv8moc6/ajmc/94ca32c0fdc82f0df4cebca00a7ffecb34f87646-4595x3436.jpg)
![summit clinical trial tirzepatide In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide Outperforms Dulaglutide on Cardiorenal](https://insightlinks.storage.googleapis.com/cardiacwire/2023/05/tirzepatide-5.8.2023-scaled-e1683241658726.jpg)
![summit clinical trial tirzepatide In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide Outperforms Dulaglutide on Cardiorenal](https://www.jacc.org/cms/10.1016/j.jacadv.2025.101740/asset/435ef5e9-d4a4-4d94-aa7b-79974b93a2be/assets/graphic/gr3.jpg)
![summit clinical trial tirzepatide In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide Outperforms Dulaglutide on Cardiorenal](https://m3.healio.com/~/media/slack-news/cardiology/misc/other/ct1122baum_pipeline-pulse_t1.jpg)
![summit clinical trial tirzepatide In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide Outperforms Dulaglutide on Cardiorenal](https://ars.els-cdn.com/content/image/1-s2.0-S0146280625000210-gr1.jpg)




















